EP2970910A4 - Ablative immunotherapy - Google Patents

Ablative immunotherapy

Info

Publication number
EP2970910A4
EP2970910A4 EP14779681.7A EP14779681A EP2970910A4 EP 2970910 A4 EP2970910 A4 EP 2970910A4 EP 14779681 A EP14779681 A EP 14779681A EP 2970910 A4 EP2970910 A4 EP 2970910A4
Authority
EP
European Patent Office
Prior art keywords
ablative
immunotherapy
ablative immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14779681.7A
Other languages
German (de)
French (fr)
Other versions
EP2970910A1 (en
Inventor
Michael Har-Noy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/796,171 external-priority patent/US9320794B2/en
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of EP2970910A1 publication Critical patent/EP2970910A1/en
Publication of EP2970910A4 publication Critical patent/EP2970910A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP14779681.7A 2013-03-12 2014-03-10 Ablative immunotherapy Ceased EP2970910A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/796,171 US9320794B2 (en) 2006-11-13 2013-03-12 Ablative immunotherapy
PCT/US2014/022287 WO2014164396A1 (en) 2013-03-12 2014-03-10 Ablative immunotherapy

Publications (2)

Publication Number Publication Date
EP2970910A1 EP2970910A1 (en) 2016-01-20
EP2970910A4 true EP2970910A4 (en) 2016-11-16

Family

ID=51658863

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14779681.7A Ceased EP2970910A4 (en) 2013-03-12 2014-03-10 Ablative immunotherapy

Country Status (11)

Country Link
EP (1) EP2970910A4 (en)
JP (1) JP6538647B2 (en)
KR (1) KR102265276B1 (en)
CN (2) CN105102613A (en)
AU (2) AU2014249374A1 (en)
BR (1) BR112015022974A8 (en)
CA (1) CA2904853A1 (en)
IL (1) IL241326B (en)
PH (1) PH12015502086A1 (en)
SG (2) SG11201507350WA (en)
WO (1) WO2014164396A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151309B (en) * 2018-02-14 2022-02-15 上海美杰医疗科技有限公司 Preoperative planning method and equipment for multi-modal ablation therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1806849A (en) * 2005-01-19 2006-07-26 上海三维生物技术有限公司 Method of treating tumors
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US20080112963A1 (en) * 2006-11-13 2008-05-15 Immunovative Therapies, Ltd. Ablative immunotherapy
WO2009095033A1 (en) * 2008-01-31 2009-08-06 Agirx Limited Vaccine compositons

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERHARD A. MÜLLER ET AL: "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", NATURE MEDICINE., vol. 6, no. 3, 1 March 2000 (2000-03-01), US, pages 332 - 336, XP055308901, ISSN: 1078-8956, DOI: 10.1038/73193 *
See also references of WO2014164396A1 *

Also Published As

Publication number Publication date
BR112015022974A2 (en) 2017-07-18
SG10201707446PA (en) 2017-10-30
AU2020201309A1 (en) 2020-03-12
EP2970910A1 (en) 2016-01-20
KR20150138234A (en) 2015-12-09
KR102265276B1 (en) 2021-06-16
CA2904853A1 (en) 2014-10-09
BR112015022974A8 (en) 2019-11-26
SG11201507350WA (en) 2015-10-29
IL241326A0 (en) 2015-11-30
WO2014164396A1 (en) 2014-10-09
IL241326B (en) 2021-05-31
AU2014249374A1 (en) 2015-09-24
CN106581673A (en) 2017-04-26
PH12015502086A1 (en) 2016-01-18
JP6538647B2 (en) 2019-07-03
JP2016518319A (en) 2016-06-23
CN105102613A (en) 2015-11-25

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
EP3000028A4 (en) Auto-calendaring
EP2957205A4 (en) Hand-dryer
GB201312133D0 (en) Immunotherapy
DK3470074T3 (en) Probiotika
EP2970310A4 (en) 5-bromo-indirubins
EP2853297A4 (en) Kendama
AU353575S (en) Stamphousing
DK3056208T3 (en) Immunpotentiator
DK2811289T3 (en) Termografisk inspektionssystem til kompositvindmøllevinge
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
SG11201507350WA (en) Ablative immunotherapy
EP3014557A4 (en) Phone-on-file
GB201300001D0 (en) Envirep - environment replicater
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
GB201322342D0 (en) Procedure
GB201318451D0 (en) W/C Sani-vent
AU353331S (en) Kettlebell

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20161019

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/26 20060101ALI20161013BHEP

Ipc: C12N 5/0783 20100101AFI20161013BHEP

Ipc: A61P 31/00 20060101ALI20161013BHEP

Ipc: A61P 35/00 20060101ALI20161013BHEP

17Q First examination report despatched

Effective date: 20171212

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20200724